SCHEMBL730574

SCHEMBL730574

[CH2]Cc1n[nH]c2ccccc12

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.52
GAA P10253 2/20 0.52
PDPK1 O15530 1/20 0.52
CYP3A4 P08684 1/20 0.52
IDO1 P14902 3/20 0.48
ALDH1A1 P00352 2/20 0.48
ALPL P05186 1/20 0.48
HPGD P15428 1/20 0.48
TTK P33981 1/20 0.48
MAPK10 P53779 1/20 0.48
CYP1A2 P05177 1/20 0.44
LRRK2 Q5S007 2/20 0.42
NPC1 O15118 1/20 0.42
TP53 P04637 1/20 0.42
RAB9A P51151 1/20 0.42
CTNNB1 P35222 1/20 0.40
WNT3A P56704 1/20 0.40
YTHDC1 Q96MU7 1/20 0.40
FGFR1 P11362 1/20 0.40
FLT1 P17948 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL730150 0.84 KDM4E (0.48) KDM4EGAAPDPK1CYP3A4IDO1
SCHEMBL731910 0.81 KDM4E (0.46) KDM4EGAAPDPK1CYP3A4IDO1
SCHEMBL3061437 0.79 KDM4E (0.52) KDM4EGAAPDPK1CYP3A4IDO1
SCHEMBL960630 0.79 KDM4E (0.52) KDM4EGAAPDPK1CYP3A4IDO1
SCHEMBL960151 0.79 KDM4E (0.52) KDM4EGAAPDPK1CYP3A4IDO1
SCHEMBL2227955 0.79 KDM4E (0.52) KDM4EGAAPDPK1CYP3A4IDO1
SCHEMBL702375 0.79 PRMT5 (0.61) KDM4EGAAPDPK1CYP3A4IDO1
SCHEMBL254885 0.79 KDM4E (0.52) KDM4EGAAPDPK1CYP3A4IDO1
SCHEMBL16182225 0.79 KDM4E (0.52) KDM4EGAAPDPK1CYP3A4IDO1
SCHEMBL29562338 0.79 KDM4E (0.52) KDM4EGAAPDPK1CYP3A4IDO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3894396-A1 2-OXOQUINAZOLINE DERIVATIVES AS METHIONINE ADENOSYLTRANSFERASE 2A INHIBITORS Ideaya Biosciences, Inc. (US) 2021-10-20 EP claimed
CN-113166078-A 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors 伊迪亚生物科学有限公司 2021-07-23 CN claimed
WO-2020123395-A1 2-OXOQUINAZOLINE DERIVATIVES AS METHIONINE ADENOSYLTRANSFERASE 2A INHIBITORS IDEAYA BIOSCIENCES, INC. (US) 2020-06-18 WO claimed
EP-2291359-A1 PHENYL OR PYRIDINYL SUBSTITUTED INDAZOLES DERIVATIVES AstraZeneca AB (SE) 2011-03-09 EP claimed
US-20100080786-A1 Phenyl or Pyridinyl Substituted Indazoles Derivatives ASTRAZENECA AB (SE) 2010-04-01 US claimed
WO-2009142569-A1 PHENYL OR PYRIDINYL SUBSTITUTED INDAZOLES DERIVATIVES ASTRAZENECA AB (SE) 2009-11-26 WO claimed
US-20240173326-A1 COMBINATION THERAPY COMPRISING A MAT2A INHIBITOR AND A TYPE II PRMT INHIBITOR IDEAYA BIOSCIENCES, INC. 2024-05-30 US disclosed
EP-4351570-A1 COMBINATION THERAPY COMPRISING A MAT2A INHIBITOR AND TYPE I PRMT INHIBITOR Ideaya Biosciences, Inc. (US) 2024-04-17 EP disclosed
EP-4347569-A1 COMBINATION THERAPY COMPRISING A MAT2A INHIBITOR AND A TYPE II PRMT INHIBITOR Ideaya Biosciences, Inc. (US) 2024-04-10 EP disclosed
US-20240108626-A1 COMBINATION THERAPY COMPRISING A MAT2A INHIBITOR AND A TYPE II PRMT INHIBITOR IDEAYA BIOSCIENCES, INC. 2024-04-04 US disclosed
WO-2023086934-A1 COMBINATION THERAPY COMPRISING A MAT2A INHIBITOR AND A TAXANE IDEAYA BIOSCIENCES, INC. (US) 2023-05-19 WO disclosed
WO-2022256806-A1 COMBINATION THERAPY COMPRISING A MAT2A INHIBITOR AND A TYPE II PRMT INHIBITOR IDEAYA BIOSCIENCES, INC. (US) 2022-12-08 WO disclosed
WO-2022256808-A1 COMBINATION THERAPY COMPRISING A MAT2A INHIBITOR AND TYPE I PRMT INHIBITOR IDEAYA BIOSCIENCES INC. (US) 2022-12-08 WO disclosed
US-4014886-A 2-Substituted-5,6-dimethoxyindazoles MORTON-NORWICH PRODUCTS, INC. (US) 1977-03-29 US disclosed
US-4009177-A Compound 2-(2-thiazolyl)-5,6-dimethoxyindazoles MORTON-NORWICH PRODUCTS, INC. (US) 1977-02-22 US disclosed
US-4009177-A Compound 2-(2-thiazolyl)-5,6-dimethoxyindazoles MORTON-NORWICH PRODUCTS, INC. (US) 1977-02-22 US disclosed
US-4002652-A 2-Substituted-5,6-dimethoxyindazoles MORTON-NORWICH PRODUCTS, INC. (US) 1977-01-11 US disclosed
US-4002652-A 2-Substituted-5,6-dimethoxyindazoles MORTON-NORWICH PRODUCTS, INC. (US) 1977-01-11 US disclosed
US-3966760-A 2-Substituted-5,6-dimethoxyindazoles MORTON-NORWICH PRODUCTS, INC. (US) 1976-06-29 US disclosed
US-3966760-A 2-Substituted-5,6-dimethoxyindazoles MORTON-NORWICH PRODUCTS, INC. (US) 1976-06-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240173326-A1 COMBINATION THERAPY COMPRISING A MAT2A INHIBITOR AND A TYPE II PRMT INHIBITOR PRMT1, PRMT6, MAT2A KDM4E 258/4885GAA 3776/4885PDPK1 2217/4885
US-20240108626-A1 COMBINATION THERAPY COMPRISING A MAT2A INHIBITOR AND A TYPE II PRMT INHIBITOR PRMT1, PRMT6, MAT2A KDM4E 258/4885GAA 3776/4885PDPK1 2217/4885
US-20100080786-A1 Phenyl or Pyridinyl Substituted Indazoles Derivatives CYP3A5, CYP3A43, ABCB1 KDM4E 3038/4885GAA 482/4885PDPK1 462/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.